These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28786345)

  • 1. BET Inhibitors as Anticancer Agents: A Patent Review.
    Ali I; Choi G; Lee K
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET inhibitors in cancer therapeutics: a patent review.
    Ghoshal A; Yugandhar D; Srivastava AK
    Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 6. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review.
    Viviano M; Cipriano A; Fabbrizi E; Feoli A; Castellano S; Sbardella G; Mai A; Milite C; Rotili D
    Expert Opin Ther Pat; 2024 Jul; 34(7):529-545. PubMed ID: 38465537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
    Sartor GC; Powell SK; Brothers SP; Wahlestedt C
    J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family.
    Radwan M; Serya R
    Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28714212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
    Sun HY; Du ST; Li YY; Deng GT; Zeng FR
    World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibitors: an updated patent review (2018-2021).
    Chen H; Liu Z; Zheng L; Wang R; Shi L
    Expert Opin Ther Pat; 2022 Sep; 32(9):953-968. PubMed ID: 35982031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.